MEET THE TEAM

Our Leadership Team and Board of Directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance, and intellectual property management.

Laura Niklason, MD, PhD
Founder, President, Chief Executive Officer:
A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine.
Dale Sander
Chief Financial Officer, Chief Corporate Development Officer, Treasurer:
A member of the Humacyte Board of Directors, Mr. Sander has served as Chief Financial Officer of six life science companies during both private and public phases, including two companies dual-listed in the U.S. and international markets.
Jeffrey Lawson, MD, PhD
Chief Surgical Officer:
A member of the Humacyte Board of Directors, Dr. Lawson is an innovator, scientist, and vascular surgeon. He has been involved in the development of Humacyte’s vascular technologies over the past 20 years in collaboration with his career-long research partner and Humacyte founder Dr. Laura Niklason.
Heather Prichard, PhD
Chief Operating Officer:
Dr. Prichard’s overall responsibility is translating the company’s innovative mission, vision and strategies into actionable activities. She brings over 20 years of strong leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials.
Juliana Blum, PhD
Co-Founder, Executive Vice President Corporate Development:
Dr. Blum has spent over 20 years combining her scientific technical expertise with bioengineered tissue development to build Humacyte’s novel biotechnology platform and bring potential therapeutic products to market. Her leadership focuses on pairing the strategic direction of the organization with the overall corporate communications and culture of the business.
Bill Tente, MS
Chief Regulatory Officer:
Mr. Tente has over 30 years of experience in the process development and manufacturing of biotherapeutic products as well as cell, gene and tissue engineering therapies for research-stage and clinical-stage companies. Tente has led teams involved with the translation of academic biomedical research to large-scale manufacturing under FDA Good Manufacturing Practices compliance.
Sabrina Osborne, GPHR, SPHR, CPC
Executive Vice President, Business Strategy & People:
Ms. Osborne has over 20 years of Human Resources, Leadership, and Organizational Development experience across Life Sciences industry. Osborne’s management experience inside and outside of the Human Resources function provides for the ability to balance business needs with management and people needs to expertly craft and implement People strategies that ensure successful business outcomes.
Kiernan DeAngelis, MD
Chief Medical Officer:
Dr. DeAngelis manages the development and implementation of clinical programs. Prior to Humacyte, He served in various Medical Director roles at IQVIA Biotech, Astra Zeneca/Pearl Therapeutics, and United Therapeutics, working to ensure the safety and scientific integrity of assigned clinical trials.
Scott Weit, PhD
Vice President of Quality:
Dr. Weit has 30 years of industry experience in leadership roles in support of pharmaceutical and biological products in commercial and research & development environments through numerous roles of increasing responsibility at Merck, Schering-Plough, Johnson & Johnson, Shire and Takeda.
A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine.

Laura E. Niklason, M.D., Ph.D.

Founder, President,
Chief Executive Officer

A member of the Humacyte Board of Directors, Mr. Sander has served as Chief Financial Officer of six life science companies during both private and public phases, including two companies dual-listed in the U.S. and international markets.

Dale Sander

Chief Financial Officer, Chief Corporate Development Officer, Treasurer

A member of the Humacyte Board of Directors, Dr. Lawson is an innovator, scientist, and vascular surgeon. He has been involved in the development of Humacyte’s vascular technologies over the past 20 years in collaboration with his career-long research partner and Humacyte founder Dr. Laura Niklason.

Jeffrey Lawson, M.D., Ph.D.

Chief Surgical Officer

Dr. Prichard's overall responsibility is translating the company’s innovative mission, vision and strategies into actionable activities. She brings over 20 years of strong leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials.

Heather Prichard, Ph.D.

Chief Operating Officer

Dr. Blum has spent over 20 years combining her scientific technical expertise with bioengineered tissue development to build Humacyte’s novel biotechnology platform and bring potential therapeutic products to market. Her leadership focuses on pairing the strategic direction of the organization with the overall corporate communications and culture of the business.

Juliana L. Blum, Ph.D.

Co-Founder,
Executive Vice President Corporate Development

Mr. Tente has over 30 years of experience in the process development and manufacturing of biotherapeutic products as well as cell, gene and tissue engineering therapies for research-stage and clinical-stage companies. Tente has led teams involved with the translation of academic biomedical research to large-scale manufacturing under FDA Good Manufacturing Practices compliance.

William Tente, M.S.

Chief Regulatory Officer

Ms. Osborne has over 20 years of Human Resources, Leadership, and Organizational Development experience across Life Sciences industry. Osborne’s management experience inside and outside of the Human Resources function provides for the ability to balance business needs with management and people needs to expertly craft and implement People strategies that ensure successful business outcomes.

Sabrina Osborne

Executive Vice President,
Business Strategy & People

Dr. DeAngelis manages the development and implementation of clinical programs. Prior to Humacyte, He served in various Medical Director roles at IQVIA Biotech, Astra Zeneca/Pearl Therapeutics, and United Therapeutics, working to ensure the safety and scientific integrity of assigned clinical trials.

Kiernan DeAngelis, M.D.

Chief Medical Officer

Dr. Weit has 30 years of industry experience in leadership roles in support of pharmaceutical and biological products in commercial and research & development environments through numerous roles of increasing responsibility at Merck, Schering-Plough, Johnson & Johnson, Shire and Takeda.

Scott Weit, Ph.D.

Vice President of Quality

History Defining Milestones

Board of Directors

Brady Dougan

Director of Humacyte since 2005
Former CEO of Credit Suisse

Robert Anderson, M.D.

Director of Humacyte since 2005
Previously served as an Independent Director to MicroIslet; former Chief of Surgery at Duke University

Carrie S. Cox

Served as Humacyte CEO from 2010 to 2018
Independent Director to Electrocore, Texas Instruments, Celgene, and Cardinal Health

Robert Langer, Sc.D.

Director of Humacyte since 2008
Serves on the Board of Moderna, Rubius Therapeutics, PureTech Health, and David H Koch Institute Professor at Massachusetts Institute of Technology.

Jeffrey Lawson, M.D., Ph.D.

Chief Surgical Officer of Humacyte
Prior to joining Humacyte in 2015, Dr. Lawson served as Professor of Surgery and Vice-Chair of the Department of Surgery at Duke University Medical Center.

Laura Niklason M.D., Ph.D.

Humacyte Founder, President, and CEO
Adjunct Professor, Yale University.

Dale Sander

Director of Humacyte since 2015
Former CFO of Avita Medical, Juventas Therapeutics, Biolex Therapeutics, and Maxim Pharmaceuticals

Kathleen Sebelius

Director of Humacyte since 2015
Former 21st Secretary of the Department of Health and Human Services. Former Governor of Kansas.

Max Wallace, JD

Director of Humacyte since 2005
Former CEO of Accelerate Brain Cancer Cure; former CEO of Cogent Neurosciences and Trimeris.

Partnerships

Scroll to Top